High prevalence of the k65r mutation in hiv-1 subtype c infected patients failing tenofovir-based first-line regimens in south africa

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Skhosana, Lindiwe ^a   Steegen, Kim ^a   Bronze, Michelle ^a   Lukhwareni, Azwidowi ^b   Letsoalo, Esrom ^a   Papathanasopoulos, Maria A ^a   Carmona, Sergio C ^a,b   Stevens, Wendy S ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PREVALENCE; SOUTH AFRICA; TREATMENT FAILURE; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; ORGANOPHOSPHONATES; PREVALENCE; SOUTH AFRICA; TENOFOVIR; VIRAL LOAD; YOUNG ADULT;

EID: 84922621245     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118145     Document Type: Article

References (31)

1. WHO (2013) Global Update on HIV treatment 2013: results, impact and opportunities. World Health Organization.
2. Fielding KL, Charalambous S, Stenson AL, Pemba LF, Martin DJ, et al. (2008) Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis 8: 93. doi: 10.1186/1471-2334-8-93 PMID: 18631397
3. Garcia de Olalla P. , Knobel H., Carmona A., Guelar A., Lopez-Colomes J.L., et al. (2002) Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 30: 105-110. PMID: 12048370
4. Novitsky V, Wester CW, DeGruttola V, Bussmann H, Gaseitsiwe S, et al. (2007) The reverse transcriptase67 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses 23: 868-878. PMID: 17678469
5. (2004) South African Antiretroviral Treatment Guidelines. In: NDoH, editor.
6. (2010) South African Antiretroviral Treatment Guidelines. In: NDoH, editor.
7. Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, et al. (2012) High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS 26: 1679-1684. doi: 10.1097/QAD.0b013e328356886d PMID: 22739389
8. Van Zyl GU, Liu TF, Claassen M, Engelbrecht S, de Oliveira T, et al. (2013) Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Sec-ond-Line Antiretroviral Treatment Regimens. PLoS One 8: e67188. PMID: 23840622
9. Hoffmann CJ, Ledwaba J, Li JF, Johnston V, Hunt G, et al. (2013) Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther 18: 915-920. doi: 10. 3851/IMP2652 PMID: 23751421
10. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164. PMID: 22156218
11. Lukhwareni A, Bronze M, Ledwaba J, Steegen K, Rossouw I, et al. Validation of a robust in-house genotyping assay for the detection of HIV-1 antiretroviral drug resistance; 2012; Cape Town, South Africa.
12. Wallis C, Papathanasopoulosa MA, Shabir Lakhib, Karitac E, Kamalid A, et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1; 2009.
13. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, et al. (2014) 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med 22: 642-650. PMID: 25101529
14. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800. PMID: 16076886
15. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739. doi: 10.1093/molbev/msr121 PMID: 21546353
16. Kuritzkes DR, Bassett RL, Hazelwood JD, Barrett H, Rhodes RA, et al. (2004) Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr 36: 600-603. PMID: 15097303
17. Sigaloff KC, Ramatsebe T, Viana R, de Wit TF, Wallis CL, et al. (2012) Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses 28: 171-175. doi: 10.1089/aid.2011.0136 PMID: 21819219
18. Wallis CL, Mellors JW, Venter WD, Sanne I, StevensW(2010) Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 53: 480-484. doi: 10.1097/QAI.0b013e3181bc478b PMID: 19801944
19. Parikh UM, Barnas DC, Faruki H, Mellors JW (2006) Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 194: 651-660. PMID: 16897664
20. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, et al. (2012) Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 54: 1660-1669. doi: 10.1093/cid/cis254 PMID: 22474222
21. Margot NA, Lu B, Cheng A, Miller MD (2006) Resistance development over 144 weeks in treatmentnaive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 7: 442-450. PMID: 16925730
22. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, et al. (2006) HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20: F9-13. PMID: 16816549
23. Coutsinos D, Invernizzi CF, Moisi D, Oliveira M, Martinez-Cajas JL, et al. (2011) A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One 6: e20208. doi: 10.1371/journal.pone.0020208 PMID: 21655292
24. Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, et al. (2013) Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis 207 Suppl 2: S70-77. doi: 10. 1093/infdis/jit114 PMID: 23687292
25. Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho RJ, et al. (2013) HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. Antimicrob Agents Chemother 57: 1053-1056. doi: 10.1128/AAC. 01668-12 PMID: 23183438
26. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, et al. (2000) HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 14: 163-171. PMID: 10708287
27. Stone C, Ait-Khaled M, Craig C, Griffin P, Tisdale M (2004) Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother 48: 1413-1415. PMID: 15047556
28. Miller MD, Margot N, Lu B, Zhong L, Chen SS, et al. (2004) Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 189: 837-846. PMID: 14976601
29. Etiebet MA, Shepherd J, Nowak RG, Charurat M, Chang H, et al. (2013) Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. AIDS 27: 553-561. doi: 10.1097/QAD.0b013e32835b0f59 PMID: 23079810
30. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA (2009) Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 12: 11. doi: 10.1186/1758-2652-12-11 PMID: 19566959
31. (2013) South African Antiretroviral Treatment Guidelines. In: NDoH, editor.